- Home
- KURA vs VSTM Comparison
KURA vs VSTM Comparison
Compare KURA & VSTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
Current Price
$8.99
HOLD
Current Price
$6.53
Company Overview
Basic Information| Metric | KURA | VSTM |
|---|---|---|
| Founded | 2014 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 830.1M | 723.8M |
| IPO Year | N/A | 2012 |
Fundamental Metrics
Financial Performance| Metric | KURA | VSTM |
|---|---|---|
| Price | $8.99 | $6.53 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 9 |
| Target Price | ★ $26.88 | $13.38 |
| AVG Volume (30 Days) | 1.4M | ★ 1.9M |
| Earning Date | 02-25-2026 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $104,029,000.00 | $13,379,000.00 |
| Revenue This Year | $109.64 | $208.54 |
| Revenue Next Year | $62.82 | $251.40 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 33.79 |
| 52 Week Low | $5.41 | $4.01 |
| 52 Week High | $12.49 | $11.25 |
Technical Indicators
Market Signals| Indicator | KURA | VSTM |
|---|---|---|
| Relative Strength Index (RSI) | 40.65 | 35.54 |
| Support Level | $8.13 | $6.31 |
| Resistance Level | $9.43 | $7.26 |
| Average True Range (ATR) | 0.49 | 0.62 |
| MACD | -0.07 | -0.03 |
| Stochastic Oscillator | 36.42 | 8.56 |
Price Performance
Historical Comparison KURA
VSTM
About KURA Kura Oncology Inc.
Kura Oncology Inc is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The company's pipeline consists of small molecule drug candidates targeting cancer signaling pathways.
About VSTM Verastem Inc.
Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.